): S1–5PubMed 33. Lorgelly PK, Joshi D, Gomara MI, et al. Exploring the cost effectiveness of an immunization programme for rotavirus gastroenteritis in the United Kingdom. Epidemiol Infect 2008; 136(1): 44–55PubMed 34. Bilcke J, Van Damme P, Beutels P. Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and ‘no medical care’ disease impact in Belgium. Med Decis Making 2009 Jan–Feb; 29(1): 33–50PubMedCrossRef
35. Mangen MJ, van Duynhoven YT, Vennema H, et al. Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program? Vaccine 2010 Mar 19; 28(14): 2624–35PubMedCrossRef 36. check details Martin A, Batty A, Roberts JA, et al. Cost-effectiveness SB525334 manufacturer of infant vaccination with RIX4414 (Rotarix) in the UK. Vaccine 2009 Jul 16; 27(33): 4520–8PubMedCrossRef 37. Panatto D, Amicizia D, Ansaldi F, et al. Burden of rotavirus disease and cost-effectiveness of universal vaccination in the Province of Genoa (Northern Italy). Vaccine 2009; 27(25–26): 3450–3PubMedCrossRef 38. Newall AT, Beutels P, Macartney K, et al. The cost-effectiveness of rotavirus vaccination in Australia. Vaccine 2007 Dec 17; 25(52): 8851–60PubMedCrossRef
39. Jit M, Edmunds WJ. Evaluating rotavirus vaccination in England and Wales: part II. The potential cost-effectiveness of vaccination. Vaccine 2007 May 16; 25(20): 3971–9PubMedCrossRef 40. Zomer TP, van Duynhoven YT, Mangen MJ, et al. Assessing the introduction of universal rotavirus vaccination in the Netherlands. Vaccine 2008 Jul 4; 26(29–30): 3757–64PubMedCrossRef 41. Chodick G, Waisbourd-Zinman O, Shalev V, et al. Potential find more impact and cost-effectiveness analysis
of rotavirus vaccination of children in Israel. Eur J Public Health 2009 Jun; 19(3): 254–9PubMedCrossRef 42. Goossens LM, Standaert B, Hartwig N, et al. Idoxuridine The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands. Vaccine 2008 Feb 20; 26(8): 1118–27PubMedCrossRef 43. Jit M, Bilcke J, Mangen MJ, et al. The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe. Vaccine 2009 Oct 19; 27(44): 6121–8PubMedCrossRef 44. Standaert B, Parez N, Tehard B, et al. Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France. Appl Health Econ Health Policy 2008; 6(4): 199–216PubMedCrossRef 45. Melliez H, Levybruhl D, Boelle PY, et al. Cost and cost-effectiveness of childhood vaccination against rotavirus in France. Vaccine 2008; 26(5): 706–15PubMedCrossRef 46. National Institute for Health and Clinical Excellence [NICE]. Guide to the methods of technology appraisal. London: NICE, 2008 Jun [online]. Available from URL: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf [Accessed 2011 Jan 5] 47. Boersma C, Broere A, Postma MJ. Quantification of the potential impact of cost-effectiveness thresholds on Dutch drug expenditures using retrospective analysis.